The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics presents promising data on RTNova™, a novel systemic virotherapy technology designed to target metastatic lung cancer and other advanced cancers by overcoming immune clearance and enhancing therapeutic targeting

A close up of a cell in the air.
Press Release
event
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics Secures Series A Investments to Advance Manufacturing

January 22, 2020
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova

The Mitchell Thorp Foundation Selects Calidi Biotherapeutics CEO to Receive the Pillars of Hope Award

December 19, 2019
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

October 9, 2019
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics Named One of the “50 Most Trustworthy Companies of The Year 2019” by the Silicon Review Magazine

September 18, 2019
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova
RTNova

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA

August 29, 2019
Discover More
Discover More
Discover More
Publication
event
NeuroNova (NNV)
NeuroNova
Supernova
RTNova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019
Discover More
Discover More
Discover More
Press Release

Calidi Biotherapeutics to Present at Jefferies Healthcare Conference

June 2, 2022
Discover More
Press Release

Calidi Biotherapeutics Granted US Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy

May 24, 2022
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of Alfonso "Chito" Zulueta, Former President of International for Eli Lilly, to Its Board of Directors

February 4, 2022
Discover More
Press Release

Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

February 2, 2022
Discover More
Press Release

Calidi Biotherapeutics Announces Dr. Maciej S. Lesniak Presentation at 13th International Oncolytic Virotherapy Conference

November 5, 2021
Discover More
Press Release

Calidi Biotherapeutics Announces Presentation at 6th Annual Oncolytic Virotherapy Summit

October 25, 2021
Discover More
Publication
event
RTNova
RTNova
NeuroNova
Supernova

Transforming all Tumor Sites: The Power of Systemic Enveloped Virotherapy

SITC 2024

November 13, 2024
Discover More
Discover More
Publication
event
RTNova
RTNova
NeuroNova
Supernova

Transforming Tumor Immune Microenvironments with a Novel Systemic Enveloped Oncolytic Virotherapy Targeting All Tumor Sites

ASCO Annual Meeting 2024

June 1, 2024
Discover More
Discover More
Publication
event
SuperNova (SNV)
SuperNova (SNV)
NeuroNova
Supernova

Non-Clinical Evidence Supporting the Upcoming CLD-201 Clinical Trial: Cell-Based Oncolytic Virotherapy for Multiple Solid Tumors

ASCO Annual Meeting 2024

June 1, 2024
Discover More
Discover More
Publication
event
NeuroNova (NNV)
NeuroNova (NNV)
NeuroNova
Supernova

Phase 1 Study of Multiple Intracerebral Doses of a Neural Stem Cell-based Oncolytic Virotherapy for Treatment of Recurrent High-grade Gliomas

ASCO Annual Meeting 2024

June 1, 2024
Discover More
Discover More
Publication
event
NeuroNova & SuperNova
NeuroNova & SuperNova
NeuroNova
Supernova

Stem Cell Platforms for Enhanced Oncolytic Virotherapy

Festival of Biologics

April 16, 2024
Discover More
Discover More
Publication
event
NeuroNova & SuperNova
NeuroNova & SuperNova
NeuroNova
Supernova

Deciphering Anticancer Mechanisms of Oncolytic Virus-loaded Stem Cells

American Association for Cancer Research

April 9, 2024
Discover More
Discover More
Media

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

February 3, 2024
Media

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

February 3, 2024
Media

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

February 3, 2024
Media

Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.

February 3, 2024
Media

Big Biz TV - Allan Camaisa

Pioneering Progress: Calidi Biotherapeutics CEO Allan Camaisa Unveils Latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023
Media

Big Biz TV - Stephen Thesing

Pioneering Progress: Calidi Biotherapeutics CBO Stephen Thesing discusses the latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023
In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023
Discover More
Discover More
In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023
Discover More
Discover More

All Courses

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more